1108684-03-2

Usage

Uses

Used in Research Applications:
(1S)-1-(4-BROMOPHENYL)PROPAN-1-AMINE is used as a research chemical for studying its psychoactive properties and potential interactions with the central nervous system. Its effects and mechanisms of action are of particular interest to scientists working in the fields of pharmacology and neuroscience.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (1S)-1-(4-BROMOPHENYL)PROPAN-1-AMINE may be utilized as a starting material or intermediate in the synthesis of new drugs targeting the central nervous system. Its unique structure and properties could contribute to the development of novel therapeutic agents for various neurological conditions.
Used in Toxicological Studies:
Understanding the safety and potential risks associated with (1S)-1-(4-BROMOPHENYL)PROPAN-1-AMINE is crucial. As such, it is used in toxicological studies to evaluate its effects on biological systems, determine safe dosages, and identify any adverse effects that may be associated with its use.

Upstream product

• 10342-83-3 4'-Bromopropiophenone 
• 374777-18-1 (R)-(+)-N-[1-(4-bromophenyl)propyl]-P,P-diphenylphosphinic amide 
• 98837-44-6 (E)-N-(4-bromobenzylidene)-P,P-diphenylphosphinic amide 
• 58824-56-9 1-(p-bromophenyl)prop-2-en-1-ol 
• 153457-05-7 1-(4-bromo-phenyl)-propanone oxime 
• 1114065-40-5 (S)-N-(1-(4-bromophenyl)propyl)-2,2,2-trifluoroacetamide 

Relevant academic research and scientific papers

One-Pot Transformation of Ketoximes into Optically Active Alcohols and Amines by Sequential Action of Laccases and Ketoreductases or ω-Transaminases

An enzymatic one-pot process for asymmetric transformation of prochiral ketoximes into alcohols or amines was developed by sequential coupling of a laccase-catalyzed deoximation either with a ketone reduction (ketoreductase, KRED) or bioamination (ω-transaminase, ω-TA) in aqueous medium. An accurate selection of biocatalysts provided the corresponding products in excellent enantiomeric excesses and overall conversions ranging from 83 to >99 % for alcohols and 70 to >99 % for amines. Likewise, the employment of exclusively 1 % (w/w) of Cremophor, a polyethoxylated castor oil, as co-solvent enabled to reach concentrations up to 100 mM in the chiral alcohols cascade.

Substituent effects on chiral resolutions of derivatized 1-phenylalkylamines by heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin GC stationary phase

Chiral resolutions of trifluoroacetyl-derivatized 1-phenylalkylamines with different type and position of substituent were investigated by capillary gas chromatography by using heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin diluted in OV-1701 as a chiral stationary phase. The influence of column temperature on retention and enantioselectivity was examined. All enantiomers of meta-substituted analytes as well as fluoro-substituted analytes could be resolved. Temperature had a favorable influence on enantioselectivity for small amines with substituents at the ortho-position. The type of substituent at the stereogenic center of amines also had a crucial effect as the ethyl group led to poor enantioseparation. Among all analytes studied, trifluoroacetyl-derivatized 1-(2′-fluorophenyl)ethylamine exhibited baseline resolution with the shortest analysis time.

Chemoenzymatic one-pot synthesis in an aqueous medium: combination of metal-catalysed allylic alcohol isomerisation-asymmetric bioamination

The ruthenium-catalysed isomerisation of allylic alcohols was coupled, for the first time, with asymmetric bioamination in a one-pot process in an aqueous medium. In the cases involving prochiral ketones, the ω-TA exhibited excellent enantioselectivity, identical to that observed in the single step. As a result, amines were obtained from allylic alcohols with high overall yields and excellent enantiomeric excesses.

CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1

This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Enantioselective addition of diethylzinc to N-diphenylphosphinoylimines employing N,N-dialkyl-1,2-diphenyl-2-aminoethanols as chiral ligands

By fine-tuning the substituents on the nitrogen of (1S,2R) and (1R,2S)-1,2-diphenyl-2-aminoethanols, a chiral ligand 2b was obtained, which showed excellent enantioselectivity, with up to 94% e.e, for the asymmetric addition of diethylzinc to N-diphenylphosphinoylimines 1. In one example, the optically active amide 3c was converted into a new amine 5 with 98% e.e. by a reaction sequence involving Suzuki coupling and hydrolysis without racemization.